Rhenman & Partners Asset Management AB / NBIX
Rhenman & Partners Asset Management AB’s Neurocrine Biosciences Inc Position
Does Rhenman & Partners Asset Management AB own Neurocrine Biosciences Inc (NBIX)? Yes — 100.8K shares worth $13M (+1.64% of its 13F portfolio) as of Q1 2026, down from 125.5K shares the prior filed quarter.
Position Value
$13M
Q1 2026
Shares
100.8K
% of Portfolio
+1.64%
Quarters Held
30
currently held
Position History NBIX
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 100.8K | $13M | +1.64% |
| Q4 2025 | 125.5K | $18M | +1.66% |
| Q3 2025 | 114.7K | $16M | +1.78% |
| Q2 2025 | 149.2K | $19M | +2.37% |
| Q1 2025 | 89.8K | $10M | +1.14% |
| Q4 2024 | 100.3K | $14M | +1.41% |
| Q3 2024 | 71.8K | $8M | +0.67% |
| Q2 2024 | 75.6K | $10M | +1.00% |
| Q1 2024 | 59.0K | $8M | +0.77% |
| Q4 2023 | 62.0K | $8M | +0.82% |
| Q3 2023 | 54.6K | $6M | +0.66% |
| Q2 2023 | 40.0K | $4M | +0.40% |
| Q1 2023 | 70.0K | $7M | +0.76% |
| Q4 2022 | 85.0K | $10M | +1.06% |
| Q3 2022 | 83.0K | $10M | +1.00% |
| Q2 2022 | 95.0K | $9M | +1.05% |
| Q1 2022 | 105.0K | $10M | +0.97% |
| Q4 2021 | 151.1K | $13M | +0.85% |
| Q3 2021 | 95.0K | $9M | +0.64% |
| Q2 2021 | 105.0K | $10M | +0.69% |
| Q1 2021 | 155.0K | $15M | +1.05% |
| Q4 2020 | 150.0K | $14M | +1.17% |
| Q3 2020 | 75.0K | $7M | +0.64% |
| Q2 2020 | 75.0K | $9M | +0.99% |
| Q1 2020 | 130.0K | $11M | +1.58% |
| Q4 2019 | 120.0K | $13M | +1.41% |
| Q3 2019 | 149.6K | $13M | +1.69% |
| Q2 2019 | 180.0K | $15M | +1.67% |
| Q1 2019 | 177.1K | $16M | +1.82% |
| Q4 2018 | 201.1K | $14M | +1.64% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Rhenman & Partners Asset Management AB’s full portfolio or all institutional holders of NBIX.